Dobutamine Injection, Solution, Concentrate
Product Images NDC 51662-1337

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Dobutamine (NDC 51662-1337). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51662 1337 2 Pouch Labeling

FDA Label Image

51662 1337 3 Case Labeling

FDA Label Image

Dosage 1 (Dosage 1)

FDA Label Image

Dosage 2 (Dosage 2)

This is a table presenting the Dobutamine infusion rate (in mL per hour) at different drug delivery rates (in mcg/kg/min) and patient body weights (in kg) for three different concentrations of Dobutamine (500 mcg/mL, 1000 mcg/mL, and 2000 mcg/mL). The table allows for the calculation of the appropriate Dobutamine infusion rate given a specific drug delivery rate, patient body weight, and Dobutamine concentration.*

FDA Label Image

How Supplied (How Supplied)

This is a medication description stating the unit of sale which is a carton containing one single-dose vial of 250mg/20mL (12.5mg/mL) concentration. The medication has an NDC code of 0409-2344-01. Additionally, the medication is also available in a tray containing ten vials with an NDC code of 0409-2344-02 as well as a 20mL single-dose vial with the NDC code of 0409-2344-62.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Label (Serialized Vial)

FDA Label Image

Structure (Structure)

FDA Label Image

Vial Label (Vial Label)

This is a description of a medication called Dobutamine Injection, USP, which is only available with a prescription. It comes in a 250 mg/20mL dosage, with each mL containing 12.5 mg of dobutamine. The medication is designed for intravenous use only and requires dilution before use. It should be used within 24 hours of dilution. Specific instructions for dosage and administration are included in an insert. The medication is manufactured by Lonkusa RL-7042 Hospira and may contain sodium hydroxide or yarochioic acid_angjor, depending on pH adjustments.*

FDA Label Image

Rfid

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.